Demographic characteristics of patients with AIIRD and controls
| Age, median (range) | Female n (%) | Disease duration, years* | Influenza vaccine n (%)† | |
| Controls, n=121 | 50 (18–90)†* | 78 (65) | NA | 89 (82.4) |
| AIIRD diagnosis, n | ||||
| All patients with AIIRD, n=686 | 59 (19–88) | 475 (69.3) | 10 (0–68) | 542 (79.4) |
| RA, n=263 | 64 (20–88) | 215 (81.75) | 10 (0–50) | 213 (82.88) |
| PsA, n=165 | 55 (20–86) | 78 (47.56) | 8 (0–68) | 120 (74.07) |
| AxSpA, n=68 | 49.5 (21–83) | 36 (52.94) | 10 (1–51) | 54 (80.6) |
| SLE, n=101 | 46 (22–80) | 89 (88.12) | 14 (0–44) | 76 (77.55) |
| IIM, n=19 | 64 (34–76) | 14 (73.68) | 2 (1–21) | 19 (100) |
| Vasculitis, n=70 | ||||
| LVV, n=21 | 70 (26–85) | 17 (80.95) | 2.5 (0–12) | 20 (95.24) |
| AAV, n=26 | 60.5 (26–85) | 14 (53.85) | 4 (0.75–28) | 22 (84.62) |
| Other vasculitis, n=23 | 56 (19–77) | 12 (52.17) | 6 (0.5–35) | 18 (78.26) |
*Data on disease duration were available for 683 patients with AIIRD (they were missing for two patients with PsA and one patient with SLE).
†Data on influenza vaccination were available for 781 participants: 673 AIIRD and 108 controls.
‡p<0.0001.
AAV, antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis; AIIRD, autoimmune inflammatory rheumatic diseases; AxSpA, axial spondyloarthritis; IIM, idiopathic inflammatory myositis; LVV, large vessel vasculitis; PsA, psoriatic arthritis; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus.